Contraindicated use of bevacizumab and toxicity in elderly patients with cancer

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3592-3599

  Hershman, Dawn L ^a,b   Wright, Jason D ^a,b   Lim, Emerson ^a,b   Buono, Donna L ^a   Tsai, Wei Yann ^a   Neugut, Alfred I ^a,b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BLEEDING; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; COLON CANCER; COLON PERFORATION; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEMOPTYSIS; HISPANIC; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; METASTATIC BREAST CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIAL STATUS; THROMBOSIS; VERY ELDERLY; AFRICAN AMERICAN; BREAST NEOPLASMS; CANCER REGISTRY; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUCASIAN; CHEMICALLY INDUCED; COHORT ANALYSIS; COLONIC NEOPLASMS; COMORBIDITY; CONTRAINDICATIONS; GASTROINTESTINAL DISEASE; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; UNITED STATES;

AFRICAN AMERICANS; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COLONIC NEOPLASMS; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; SEER PROGRAM; UNITED STATES;

EID: 84891498064     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4857     Document Type: Article

References (36)

1. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
4. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
5. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
6. Genentech package insert. 2012
7. https://online.epocrates.com/noFrame/show Page.do?method-drugs&MonographId-3619&Active SectionId-10
8. Mullins CD, Montgomery R, Tunis S: Uncertainty in assessing value of oncology treatments. Oncologist 15:58-64, 2010 (suppl 1)
9. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
10. World Health Organization: International Classification of Disease (9th revision). Geneva, Switzerland, 2008
11. Hershman DL, Buono DL, Malin J, et al: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101:1633-1641, 2009
12. Du XL, Fang S, Vernon SW, et al: Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660-669, 2007
13. Charlson ME, Sax FL, MacKenzie CR, et al: Assessing illness severity: Does clinical judgment work? J Chronic Dis 39:439-452, 1986
14. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
15. Potosky AL, Warren JL, Riedel ER, et al: Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62-8, 2002
16. Gotay CC: Increasing trial generalizability. J Clin Oncol 24:846-847, 2006
17. Markman M: Outcomes when cancer treatment is delivered on, or off, a clinical trial: Implications for generalizability of study results. Oncology 81:141-142, 2011
18. Al-Refaie WB, Vickers SM, Zhong W, et al: Cancer trials versus the real world in the United States. Ann Surg 254:438-442, 2011; discussion 42-43
19. NIH Revitalization Act. Subtitle B:131-133. 1993
20. Unger JM, Coltman CA Jr, Crowley JJ, et al: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24:141-144, 2006
21. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and agebased disparities. JAMA 291:2720-2726, 2004
22. Hershman DL, Wilde ET, Wright JD, et al: Uptake and economic impact of first-cycle colonystimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 30:806-812, 2012
23. Wright JD, Neugut AI, Wilde ET, et al: Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 29:3408-3418, 2011
24. Lerose R, Musto P, Aieta M, et al: Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience. Eur J Clin Pharmacol 68:505-512, 2012
25. Tsai TT, Maddox TM, Roe MT, et al: Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 302:2458-2464, 2009
26. Keating NL, Kouri E, He Y, et al: Racial differences in definitive breast cancer therapy in older women: Are they explained by the hospitals where patients undergo surgery? Med Care 47:765-773, 2009
27. Freedman RA, Virgo KS, He Y, et al: The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 117:180-189, 2011
28. Black-white disparities in health care. JAMA 263:2344-2346, 1990
29. Jirillo A, Vascon F, Giacobbo M: Bevacizumab in advanced cancer, too much or too little? Ann Oncol 19:1817-1818, 2008
30. Dawood S, Shaikh AJ, Buchholz TA, et al: The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118:2780-2786, 2012
31. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
32. Ray WA, Stein CM: Reform of drug regulation-Beyond an independent drug-safety board. N Engl J Med 354:194-201, 2006
33. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002
34. Smith GL, Smith BD, Buchholz TA, et al: Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26:5119-5125, 2008
35. Giordano SH, Lee A, Kuo YF, et al: Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 107:423-432, 2006
36. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006